[Pubmed] Complement inhibitor therapy as a steroid-sparing strategy in generalized myasthenia gravis
Posté : 02 juin 2025 12:00
Ther Adv Neurol Disord. 2025 May 30;18:17562864251332037. doi: 10.1177/17562864251332037. eCollection 2025.
ABSTRACT
BACKGROUND: Standard management of generalized myasthenia gravis associated with anti-acetylcholine receptor autoantibodies (AChR-gMG) includes corticosteroids and nonsteroidal immunosuppressants. Complement inhibitors (CI) represent a more tailored therapeutic strategy. Real-world data on the steroid-sparing efficacy of CI remain limited.
OBJECTIVE: To investigate the steroid-sparing efficacy of CI in AChR-gMG.
DESIGN: We identified 69 AChR-gMG patients on corticosteroids treated with azathioprine (AZA), mycophenolate mofetil (MMF), or CI.
METHODS: Steroid tapering was assessed by comparing corticosteroid dosage at several time-points to baseline.
RESULTS: Steroids reductions were statistically significant for all therapies at every time point compared to baseline (all p < 0.001). Pairwise comparisons using the Mann-Whitney U test revealed significant differences between CI and MMF at 3 months (p = 0.0372), 6 months (p = 0.0193), and 9 months (p = 0.0321) and between CI and AZA at 6 months (p = 0.0415).
CONCLUSION: CI rapidly and effectively reduced corticosteroid dosage in most AChR-gMG patients, suggesting their potential role as steroid-sparing therapeutic options.
PMID:40453104 | PMC:PMC12126683 | DOI:10.1177/17562864251332037
Source: https://pubmed.ncbi.nlm.nih.gov/4045310 ... t9+e462414